Meda turns down Mylan – again
This article was originally published in Scrip
Executive Summary
Meda confirmed that it has rejected a second acquisition bid by US generics company Mylan. The revised offer comes hot on the heels of Mylan's first approach which was reported at the start of this month (scripintelligence.com, 4 April 2014).